Introduction
============

Myocardial injury (MI) following non-cardiac surgery is a significant international public health concern, occurring in \~8% of such surgeries and causing mortality in 10% of affected patients within 30 days of surgery ([@b1-etm-0-0-5139]). The pathophysiology of perioperative MI remains poorly understood, and reliable methods do not yet exist to predict the risk of such injury in individual patients ([@b2-etm-0-0-5139],[@b3-etm-0-0-5139]).

MI subsequent to non-cardiac surgery may be caused by preoperative endothelial dysfunction, with \~58% of patients with this dysfunction developing postoperative MI ([@b4-etm-0-0-5139]). Endothelial dysfunction compromises the proper regulation of vascular tone, thrombosis and inflammation ([@b5-etm-0-0-5139]), and increases the risk of atherosclerosis and thromboembolic events ([@b6-etm-0-0-5139]). Coronary artery endothelial dysfunction increases the risk of adverse cardiovascular events ([@b2-etm-0-0-5139],[@b7-etm-0-0-5139],[@b8-etm-0-0-5139]), and preoperative brachial arterial endothelial dysfunction is independently predictive of short- and long-term postoperative cardiovascular events in patients undergoing vascular surgery ([@b9-etm-0-0-5139],[@b10-etm-0-0-5139]). Perioperative endothelial dysfunction may be a risk factor for postoperative cardiovascular events, and assessment of endothelial function using non-invasive measures prior to and following non-cardiac surgery may assist clinicians to prevent and treat postoperative MI ([@b4-etm-0-0-5139]).

Postoperative pain may impair the endothelial function and increase the risk of endothelial dysfunction, consequently leading to acute coronary syndrome ([@b11-etm-0-0-5139]). In addition, pain is negatively correlated with perioperative endothelial function ([@b11-etm-0-0-5139]). This raises the question of whether appropriate pain management following non-cardiac surgery is able to reduce the risk of endothelial dysfunction. In support of this hypothesis, postoperative pain management, such as the epidural blockade of thoracic sympathetic segments using local anesthetics, has been demonstrated to reduce risk of MI ([@b12-etm-0-0-5139]--[@b15-etm-0-0-5139]).

To test the hypothesis that postoperative pain control may help reduce endothelial dysfunction, a randomized controlled investigation was performed in the present study, comparing the analgesic effects of tramadol against a placebo. The results may help guide clinical practices for reducing the risk of MI subsequent to non-cardiac surgery and may help clarify the poorly understood mechanisms underlying this injury.

Materials and methods
=====================

### Subjects

This randomized, double-blind, placebo-controlled study was performed in Chongqing Medical University (Chongqing, China). Patients aged 20--60 years who were undergoing laparoscopic cholecystectomy involving standardized total intravenous anesthesia (TIVA) at Chengdu Women and Children\'s Central Hospital (Chengdu, China) between January 2014 and November 2015 were eligible to participate in the present study ([@b16-etm-0-0-5139]). The exclusion criteria were as follows: Patients undergoing emergency surgery; patients classified as grade IV or V on the American Society of Anesthesiologists scale ([@b11-etm-0-0-5139]); patients declining to be analyzed postoperatively; or patient with unstable postoperative vital signs.

In order to estimate an adequate sample size, it was hypothesized that the placebo group would experience 70% reduction in the endothelial function, while the tramadol group would experience a 30% reduction, based on the findings of previous studies on endothelial dysfunction ([@b17-etm-0-0-5139],[@b18-etm-0-0-5139]). Assuming a baseline flow-mediated dilation (FMD) of 7.0±1.5%, it was calculated that 80 patients in each group should provide 80% power to detect a change in the FMD at α=0.05.

### Group allocation and interventions

Patients were assigned to the tramadol or saline (placebo) groups in a 1:1 ratio using software-driven randomization. All subjects completed a questionnaire in order to provide the baseline clinicodemographic data, including the present complaints, as well as personal and family medical history. Pain severity was assessed using a modified visual analogue scale (VAS) ([@b11-etm-0-0-5139]) with scores between 0 (no pain) and 10 (extremely painful). This scale has demonstrated a test-retest reliability intraclass correlation of 0.87 for repeated scoring ([@b11-etm-0-0-5139]). Brachial artery FMD and endothelium-independent dilation, which is referred to as the nitroglycerin (NTG)-induced dilation, were measured on preoperative day 1 (baseline).

All participants received intravenous glycopyrrolate (0.2 mg; Carbosynth Ltd., Compton, UK) as premedication, followed by TIVA that was performed as described previously ([@b16-etm-0-0-5139]). Briefly, TIVA was induced using propofol (2 mg/kg; Yichang Humanwell Pharmaceutical Co., Ltd., Yichang, China) and fentanyl (0.3 µg/kg; Yichang Humanwell Pharmaceutical Co., Ltd.) target-controlled infusions (TCIs), administered using a two-channel infusion pump. Intravenous rocuronium (0.6 mg/kg; Yichang Humanwell Pharmaceutical Co., Ltd.) was also administered for neuromuscular blockade. Following tracheal intubation, propofol and fentanil TCIs were titrated to maintain the bispectral index between 40--60, and the systolic blood pressure and heart rate within ± 20% of their baseline values. Participants received a single intravenous dose of ondansetron (4 mg, Yichang Humanwell Pharmaceutical Co., Ltd.) to prevent postoperative nausea and vomiting. Routine monitoring consisted of electrocardiography, pulse oximetry, non-invasive arterial pressure, end-tidal carbon dioxide partial pressure and bispectral index measurement.

For postoperative pain management, patients in the tramadol group were administered intravenous, patient-controlled tramadol prior to transporting to the recovery room. The delivery settings were a bolus dose of 10 mg (Yichang Humanwell Pharmaceutical Co., Ltd.), followed by a lock-out time of 10 min and a basal infusion rate of 10 mg/h. Patients in the placebo group received 0.9% saline. If VAS scores were \>4, patients were given intravenous fentanyl (20 µg) repeatedly until the score fell \<4 ([@b19-etm-0-0-5139]). The number of patients requiring rescue analgesia was recorded. The VAS scores, FMD and NTG-induced dilation were again examined at 2 h, 1 day and 5 days postoperatively.

### Measurement of FMD and NTG-induced dilation

The flow-mediated and NTG-induced dilations were both examined in the present study, since these function through different mechanisms. In FMD, increased blood flow stimulates the release of vasodilators, such as nitric oxide, from the endothelium and causes arterial dilation. By contrast, NTG functions directly on the arterial smooth muscle and induces endothelium-independent dilation ([@b11-etm-0-0-5139]).

The FMD and NTG-induced dilation were measured using ultrasound as previously described ([@b20-etm-0-0-5139],[@b21-etm-0-0-5139]). Briefly, the brachial artery diameter was measured using high-resolution B-mode ultrasound under three conditions: At rest, in response to reactive hyperemia, and following sublingual exposure to nitroglycerin (400 µg). An L10-5 linear array transducer with a median frequency of 7.5 MHz and a standard ATL HDI 5,000 ultrasound system (Philips Healthcare, Amsterdam, The Netherlands) were used. Reactive hyperemia was induced by inflating a pneumatic tourniquet around the forearm, which had been positioned distal to the segment of the artery being scanned, to a pressure of 220--240 mmHg for 4.5 min, followed by release. Doppler-derived arterial flow was measured at rest and during hyperemia.

These procedures were conducted in a quiet environment, and no significant alterations in the heart rate or blood pressure were observed. These procedures have been demonstrated to be accurate and reproducible, with a low interobserver error ([@b11-etm-0-0-5139]). In our previous studies, excellent reliability was routinely achieved, with the FMD presenting a mean relative difference of only 3% within individual patients ([@b22-etm-0-0-5139],[@b23-etm-0-0-5139]).

All measurement sessions were recorded on Super-VHS videotape for subsequent off-line analysis by an investigator blinded to the subject identity, group allocation and time point (pre- or postoperative). The same investigator analyzed videos of all participants.

### Statistical analysis

Data are expressed as the mean ± standard deviation. Collected data were evaluated using an analysis of covariance model. Differences in the clinical and vascular parameters were compared with baseline among the three postoperative periods (2 h, 1 day, 5 days) and significant differences were determined by repeated-measures analysis of variance. Multiple comparisons between groups were performed using Student-Newman-Keuls post-hoc test. Backward stepwise multivariate analysis of variance with Tukey\'s post-hoc test was performed to estimate the major determinants of the FMD data, including age, VAS, systolic and diastolic blood pressures, heart rate and reactive hyperemia. Statistical analysis was performed using SPSS software 18.0 (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Baseline characteristics

A total of 160 patients were enrolled into the current study and randomized into the tramadol and placebo groups ([Fig. 1](#f1-etm-0-0-5139){ref-type="fig"}). However, 2 participants in the placebo group were excluded since they had to undergo open cholecystectomy due to dense inflammatory adhesions. Thus, 158 patients completed the study, with a mean age of 43.8±14.0 years (range, 20--60 years). The tramadol and placebo groups were similar with regard to their major clinicodemographic characteristics and vascular function indicators ([Table I](#tI-etm-0-0-5139){ref-type="table"}), including the age, body mass index (BMI), pain history, dosage and type of anesthetic and vasoactive drugs, volume of fluid supplementation, surgical time and volume of intraoperative hemorrhage. No patient developed significant perioperative cardiovascular complications.

### General clinical and vascular parameters

The tramadol and placebo groups demonstrated similar blood flow and reactive hyperemia at all four time points. At 2 h postoperatively, the blood pressure and heart rate were significantly higher in the two groups compared with these values at the other three time points (P\<0.05). In addition, at 2 h postoperatively, the blood flow was significantly greater in comparison with that at baseline in the two groups (P\<0.05), whereas reactive hyperemia was significantly lower (P\<0.01), although shear rate remained unchanged. The tramadol and placebo groups demonstrated stable responses to NTG throughout surgery ([Table II](#tII-etm-0-0-5139){ref-type="table"}).

### FMD, NTG-induced dilation and VAS score

FMD was significantly higher in the tramadol group as compared with that in the placebo group at 2 h postoperatively (6.7±1.5 vs. 6.0±1.7%; P=0.001; [Table III](#tIII-etm-0-0-5139){ref-type="table"}) and at 1 day postoperatively (7.1±1.3 vs. 6.9±1.4%; P=0.03; [Fig. 2A](#f2-etm-0-0-5139){ref-type="fig"}). FMD decreased significantly between the baseline and 2 h postoperatively in the tramadol (P=0.002) and placebo groups (P\<0.05; [Fig. 2B](#f2-etm-0-0-5139){ref-type="fig"}). Conversely, the VAS score increased significantly over the same period in the two groups (P\<0.05). Since the two groups had similar FMD at baseline, this indicates that tramadol was associated with a smaller decrease in the FMD following surgery, which later returned to similar levels for the two groups at 5 days postoperatively. Furthermore, the NTG-induced dilation were stable throughout the various time points in the two groups, ranging between 16.8±2.3 and 18.6±2.6% in the tramadol group (P\>0.20; [Table II](#tII-etm-0-0-5139){ref-type="table"}).

The VAS score was significantly lower in the tramadol group when compared with that in the placebo group at 2 h (2.8±1.9 vs. 3.2±2.3; P=0.013) and 1 day postoperatively (1.4±1.0 vs. 1.7±1.8; P=0.031; [Fig. 2C](#f2-etm-0-0-5139){ref-type="fig"}). Across the two patient groups and all four time points, a VAS score of ≥5 was independently associated with postoperative FMD of \<7% \[odds ratio (OR), 2.7; 95% confidence interval (95% CI), 0.9--5.0; P=0.041\]. Conversely, a VAS score of \<5 at 2 h postoperatively in the tramadol group was independently associated with an FMD value of ≥7% (OR, 2.5; 95% CI, 1.0--6.0; P=0.047). The total fentanyl consumption was also significantly lower in the tramadol group in comparison with that in the placebo group (37.4±36.8 vs. 53.7±37.1; P\<0.05).

Backward stepwise multiple linear regression identified several independent correlations between the clinicodemographic variables and FMD value of patients at 2 h postoperatively ([Table IV](#tIV-etm-0-0-5139){ref-type="table"}). The FMD value was found to be negatively correlated with the age (B=−1.403; P=0.011), VAS score (B=−0.579; P=0.003) and BMI of patients (B=−0.551; P=0.010). In addition, the FMD at 2 h postoperatively was positively correlated with the FMD at the baseline (B=1.186; P\<0.001).

Discussion
==========

The results of the present relatively small randomized, double-blind trial suggested that analgesic treatment following laparoscopic cholecystectomy may lead to improved arterial endothelial function postoperatively. In addition, this improved endothelial function appears to be correlated with a lower incidence of MI. In particular, a VAS score of \<5 appeared to be associated with a lower risk of MI.

In the present study on laparoscopic cholecystectomy, the FMD in the two groups significantly decreased below the baseline value at 2 h postoperatively and remained at low levels for at least 1 extra day, showing recovery at 5 days postoperatively. This timescale of postoperative FMD alterations is consistent with studies examining other types of non-cardiac surgery ([@b11-etm-0-0-5139],[@b18-etm-0-0-5139],[@b24-etm-0-0-5139],[@b25-etm-0-0-5139]). For instance, FMD decreased significantly compared with the baseline value during the first 24 h after knee replacement surgery, recovering to the baseline levels by 7 days postoperatively ([@b18-etm-0-0-5139]). In addition, endothelial function significantly improved in patients within 2 weeks postoperatively following renal transplant surgery ([@b24-etm-0-0-5139]), and 28 days after femoropopliteal bypass surgery ([@b25-etm-0-0-5139]). These past and present findings are consistent with the hypothesis that alterations in the arterial endothelial function during the perioperative period contribute to perioperative myocardial infarction and other cardiovascular events, since these events usually occur within 3 days after surgery ([@b26-etm-0-0-5139]). The current study observed that the FMD level was significantly improved at 2 h postoperatively in the tramadol group as compared with that in the placebo group, suggesting that analgesic treatment may improve the arterial endothelial function and thereby reduce the risk of MI.

Tramadol may exert these effects by reducing the stress response to surgery and pain ([@b14-etm-0-0-5139],[@b15-etm-0-0-5139]). Perioperative trauma and pain cause stress reactions, as well as the release of proinflammatory cytokines, including C-reactive protein, tumor necrosis factor α, interleukin (IL)-1, IL-6 and IL-8. Stress reactions and proinflammatory cytokines may then inhibit the FMD by impairing nitric oxide production ([@b11-etm-0-0-5139],[@b27-etm-0-0-5139]--[@b29-etm-0-0-5139]). Indeed, IL-6 is a marker of endothelial dysfunction, and elevated levels of this cytokine are associated with a low FMD in patients suffering from myocardial infarction ([@b29-etm-0-0-5139]). Thoracic epidural analgesia can reduce the stress responses to surgery and pain by blocking the neuroendocrine pathway ([@b14-etm-0-0-5139]). Micromolar concentrations of morphine inhibit the lipopolysaccharide-induced synthesis of IL-6 ([@b30-etm-0-0-5139]). However, even in patients receiving pain relief by tramadol through a patient-driven system, the FMD at 2 h postoperatively was significantly lower compared with the baseline level, supporting the hypothesis that arterial endothelial dysfunction in the early postoperative period may help drive MI. It is possible that the MI observed in the tramadol group in the current study was due to 'non-obstructive' vulnerable plaques ([@b2-etm-0-0-5139]). These plaques cannot be detected by myocardial studies to investigate whether postoperative VAS scores of ≥5 may be a predictor of MI following non-cardiac surgery.

The present study has several limitations. Larger sample sizes and higher-risk cohorts should be examined in the longer term in order to fully explore the correlation of analgesic treatment and endothelial function with postoperative cardiovascular complications. In addition, whether the included patients took off-study drugs, antibiotics, vitamins, potassium chloride or other antihemorrhagic treatment cannot be excluded, which may have influenced the endothelial function and therefore interfered with our results. However, it was confirmed that the tramadol and placebo groups were similar in terms of the dose and type of anesthetic and vasoactive drugs, surgery duration and clinicodemographic characteristics.

In conclusion, the present study suggested that analgesic treatment was able to improve arterial endothelial function following non-cardiac surgery. This strengthens the previously described link between postoperative pain and vascular endothelial function; postoperative pain could impair endothelial function, leading to postoperative MI. This could inform a new treatment approach to decrease the incidence of postoperative acute coronary syndrome. More prospective work on large cohorts is needed to confirm this.

![CONSORT flow diagram demonstrating the division of the study participants through each stage of the trial. Two participants in the placebo group were excluded as they had to undergo open cholecystectomy due to dense inflammatory adhesions.](etm-14-05-4767-g00){#f1-etm-0-0-5139}

![Comparison of brachial FMD and VAS pain score between patients in the tramadol or placebo group at the baseline and three postoperative time points. (A) Comparison of FMD. ^§^P=0.001 and \*P=0.015 vs. placebo group. (B) Alterations in the brachial FMD at different time points in the two groups. (C) Comparison of VAS scores in the groups. \*P\<0.05 vs. placebo group. FMD, flow-mediated dilation; VAS, visual analogue scale.](etm-14-05-4767-g01){#f2-etm-0-0-5139}

###### 

Clinicodemographic characteristics and indicators of vascular reactivity in patients receiving analgesic or placebo treatment subsequent to laparoscopic cholecystectomy.

  Characteristic                        Tramadol (n=80)   Saline (n=80)
  ------------------------------------- ----------------- ---------------
  Age, years                            56.8±10.1         57.0±11.2
  Male: female, n                       28:32             26:34
  Risk classification, n                                  
    ASA grade I                         32                34
    ASA grade II                        28                26
  Surgical time, min                    65.3±10.2         64.2±9.6
  Laboratory results                                      
    TC (mmol/l)                         5.23±0.82         5.31±1.02
    TG (mmol/l)                         1.72±1.21         1.68±0.65
    Urea nitrogen (mmol/l)              4.71±0.73         4.66±1.15
    Creatinine (mmol/l)                 74.9±13.1         75.2±11.8
    Glucose (mmol/l)                    5.28±1.10         4.36±3.01
  Vascular reactivity                                     
    Brachial FMD (%)                    7.0±1.5           6.9±1.4
    Brachial NTG-induced dilation (%)   16.8±2.3          16.3±2.7
  Blood flow, ml/min                    23.6±12.8         20.4±9.1
  Shear rate, ×103/sec                  81.2±20.8         86.0±21.9
  Reactive hyperemia (%)                425±102           417.5±191.3
  VAS score                             0.8±1.3           0.6±1.1
  Blood pressure (mmHg)                                   
    Systolic                            113.1±15.2        115.4±17.6
    Diastolic                           71.9±9.3          72.3±8.51
  Heart rate (bpm)                      75.3±6.2          72.1±9.6

Values expressed as the mean ± standard deviation. ASA, American Society of Anesthesiologists; FMD, flow-mediated dilation; NTG, nitroglycerin-induced dilation; TC, total blood cholesterol; TG, triglycerides; VAS, visual analogue scale.

###### 

Vascular parameters at different time points in patients receiving analgesic or placebo treatment following laparoscopic cholecystectomy.

                                   Tramadol group   Placebo (saline) group                                                                    
  -------------------------------- ---------------- ------------------------ ------------ ------------ ------------ ------------ ------------ ------------
  Systolic blood pressure, mmHg    113.1±15.2       124.0±24.2               110.0±14.5   113.1±18.0   115.4±17.6   124.7±15.9   113.3±14.8   117.1±21.1
  Diastolic blood pressure, mmHg   71.9±9.3         75.8±15.2                72.5±11.2    71.8±9.5     72.3±8.51    76.2±10.4    73.2±7.8     69.8±9.3
  Heart rate, bpm                  75.3±6.2         94.7±12.2                81.7±13.9    74.9±12.3    72.1±9.6     95.7±12.7    77.4±11.6    76.2±9.8
  Blood flow, ml/min               23.6±12.8        29.7±9.6                 24.1±10.0    24.4±6.7     20.4±9.1     29.8±7.6     22.4±16.4    26.9±14.8
  Shear rate, ×10^3^/sec           81.2±20.8        84.7±16.4                80.2±25.5    82.3±21.6    86.0±21.9    83.2±22.8    81.2±19.8    83.4±23.8
  Hyperemia, %                     425±102          389±105                  461±157      425±102      417±191      396±110      441±90       393±123
  NTG-induced dilation, %          16.8±2.3         17.2±3.1                 17.3±3.9     18.6±2.6     16.3±2.7     16.4±3.2     16.9±4.7     17.1±3.7

Values are expressed as the mean ± standard deviation. NTG, nitroglycerin.

###### 

Comparison of brachial FMD and VAS scores at different times in patients receiving analgesic or placebo treatment following laparoscopic cholecystectomy.

                       Tramadol group   Placebo (saline) group             
  -------------------- ---------------- ------------------------ --------- -------------------------------------------------------
  Preoperative day 1   0.8±1.3          7.0±1.5                  0.6±1.1   6.9±1.4
  Postoperative                                                            
  2 h                  3.0±1.7          6.7±1.5                  3.1±1.5   6.0±1.7^[a](#tfn3-etm-0-0-5139){ref-type="table-fn"}^
    Day 1              1.1±1.0          7.1±0.9                  1.1±1.2   6.9±1.2^[b](#tfn4-etm-0-0-5139){ref-type="table-fn"}^
    Day 5              1.1±1.3          7.3±1.6                  0.9±1.0   7.1±1.3

P=0.001

P\<0.05 vs. placebo group. Values are expressed as the mean ± standard deviation. VAS scores were between 0 and 10. FMD, flow-mediated dilation; VAS, visual analogue scale.

###### 

Correlation analysis to identify the predictors of FMD (%) at 2 h postoperatively in all patients.

  Factor             B-value   β        P-value
  ------------------ --------- -------- ---------
  Age                −1.403    −0.913   0.011
  VAS score          −0.579    −0.996   0.003
  Baseline FMD (%)   1.186     0.998    \<0.001
  BMI                −0.551    −0.992   \<0.001
  Hyperemia (%)      0.005     0.17     0.066

VAS scores were between 0 and 10. BMI, body mass index; FMD, flow-mediated dilation; VAS, visual analogue scale.

[^1]: Contributed equally
